Compare CRDF & AMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRDF | AMTX |
|---|---|---|
| Founded | 1999 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.5M | 98.6M |
| IPO Year | 2012 | 2023 |
| Metric | CRDF | AMTX |
|---|---|---|
| Price | $1.93 | $1.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $9.63 | ★ $17.00 |
| AVG Volume (30 Days) | ★ 989.3K | 828.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.37 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $365,993.00 | ★ $77,194,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $139.04 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 49.61 | ★ 174.60 |
| 52 Week Low | $1.48 | $1.22 |
| 52 Week High | $4.56 | $3.66 |
| Indicator | CRDF | AMTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.82 | 42.92 |
| Support Level | $1.48 | $1.38 |
| Resistance Level | $2.41 | $1.65 |
| Average True Range (ATR) | 0.11 | 0.08 |
| MACD | 0.08 | -0.01 |
| Stochastic Oscillator | 78.64 | 11.63 |
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
Aemetis Inc is an renewable fuel and biochemicals company focused on the production of renewable fuels and chemicals through the acquisition, development and commercialization of technologies that replace traditional petroleum-based products through the conversion of first-generation ethanol and biodiesel plants into biorefineries. It owns and operates an approximately 65 million gallon per year ethanol production facility located in Keyes, California. In addition to low carbon renewable fuel ethanol, the Keyes Plant produces Wet Distillers Grains, Distillers Corn Oil, and Condensed Distillers Solubles, all of which are sold to local dairies and feedlots as animal feed. It operates in the reportable geographic segments of North America and India.